Pernix Therapeutics Holdings has reported a net loss of $270,342, or $0.01 per share, for the third quarter ended 30 September 2012 compared to a net income of $1.99m, or $0.08 per share, for thesame period in 2011.
Net sales for the third quarter of 2012 were $18.13m compared to $17.06m last year.
The company reported a net loss of $10,911, or $0 per share, for the nine months ended 30 September 2012 as against net income of $4.47m, or $0.19 per share, in 2011.
Net sales for the first nine months in 2012 increased to $43.11m from $39.20m during the same period in 2011.
Pernix president and chief executive officer Cooper Collins said the company, during the third quarter, launched Omeclamox-Pak and the generic Spinosad for the treatment of head lice, and upgraded the Great Southern Labs.
"Today, we announced that we entered into an agreement to acquire Cypress Pharmaceuticals and Hawthorn Pharmaceuticals, which are an excellent combination with Pernix and are expected to provide strong growth for the Company in the future," Collins added.
The company anticipates its combined annual revenues for 2013 to be in the range of $135m to $145m, with the addition of Cypress and Hawthorn.
